Prophylaxis Results Set Stage For Expanded Japan Xofluza Use
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.
You may also be interested in...
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.